| Identification | Back Directory | [Name]
LHF-535 | [CAS]
1450929-77-7 | [Synonyms]
LHF-535
inhibit,LHF-535,Arenavirus,LHF 535,Inhibitor,LHF535
Benzenemethanol, a,a-dimethyl-4-[(1Z)-2-[1-[4-(1-methylethoxy)phenyl]-1H-benzimidazol-5-yl]ethenyl]- | [Molecular Formula]
C27H28N2O2 | [MDL Number]
MFCD32062755 | [MOL File]
1450929-77-7.mol | [Molecular Weight]
412.53 |
| Chemical Properties | Back Directory | [Boiling point ]
597.9±52.0 °C(Predicted) | [density ]
1.10±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 96.67 mg/mL (234.34 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.46±0.29(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively[1]. | [in vivo]
LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver[2].
An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection in mice[2]. | Animal Model: | IFN-α/β and-γ receptor-deficient AG129 mice[2] | | Dosage: | 3, 10, or 30 mg/kg/day | | Administration: | Orally; daily; 14 days | | Result: | Effective as a post-exposure therapeutic. |
| [References]
[1] Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2.
[2] Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439. DOI:10.1371/journal.ppat.1007439 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|